Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, AbCellera Biologics Inc. (ABCL) has a Wall Street consensus price target of $20.17, based on estimates from 11 covering analysts. With the stock currently trading at $3.61, this represents a potential upside of +458.7%. The company has a market capitalization of $1.09B.
Analyst price targets range from a low of $5.00 to a high of $34.00, representing a 144% spread in expectations. The median target of $23.50 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ABCL trades at a trailing P/E of -7.4x. Analysts expect EPS to grow -31.9% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ABCL stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for ABCL is $20.17, representing 458.7% upside from the current price of $3.61. With 11 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ABCL has a consensus rating of "Buy" based on 11 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $20.17 implies 458.7% upside from current levels.
ABCL's current price is $3.61 with a consensus target of $20.17 (458.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $34 for ABCL, while the most conservative target is $5. The consensus of $20.17 represents the median expectation. These targets typically reflect 12-month expectations.
ABCL is moderately covered, with 11 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ABCL stock forecast based on 11 Wall Street analysts shows a consensus price target of $20.17, with estimates ranging from $5 (bear case) to $34 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on ABCL, with a "Buy" consensus rating and $20.17 price target (458.7% upside). 9 of 11 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ABCL analyst price targets range from $5 to $34, a 144% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $20.17 consensus represents the middle ground.